Bossuyt Patrick M
Department Epidemiology & Data Science, Amsterdam University Medical Centers, University of Amsterdam, PO Box 22700, 1100 DE, Amsterdam, The Netherlands.
Dig Dis Sci. 2025 May;70(5):1668-1675. doi: 10.1007/s10620-024-08800-3. Epub 2025 Jan 22.
Like all interventions in health care, novel non-invasive tests for colorectal cancer should be properly evaluated before they can be recommended. Such evaluations should be performed in well-designed studies, of which the results can serve as the evidence base for recommendations. While the methods for evaluating novel tests have been slower to develop, there is now a solid base for developing suggestions and even strong recommendations for their assessment. These include advice for study design, analysis of results, and clear and informative reporting. These considerations should be guided by the intended use of the new test and its role in the testing pathway. We distinguish between tests proposed as a replacement for an existing test, as a triage test, before an existing test, or as an add-on test, after an existing test. We recommend the definition of explicit, a priori defined, minimally acceptable performance criteria for the intended use of the new test and rigorous statistical hypothesis testing, to prevent "spin" in the interpretation of the findings.
与医疗保健中的所有干预措施一样,新型非侵入性结直肠癌检测在被推荐之前应进行适当评估。此类评估应在设计良好的研究中进行,研究结果可作为推荐的证据基础。虽然评估新型检测的方法发展较为缓慢,但现在已有坚实基础来制定关于其评估的建议甚至强有力的推荐。这些包括研究设计建议、结果分析以及清晰且信息丰富的报告。这些考量应以新检测的预期用途及其在检测流程中的作用为指导。我们区分作为现有检测替代方案、分流检测(在现有检测之前)或附加检测(在现有检测之后)提出的检测。我们建议为新检测的预期用途定义明确的、先验定义的、最低可接受性能标准,并进行严格的统计假设检验,以防止在结果解释中出现“夸大”情况。